An Editorial Note on Proteochemometrics
Abstract
One of the most important phases of a drug discovery campaign is the discovery of a potent inhibitor to a target driving the disease phenotype. Experimental design, make, test cycles seek to optimize initial hits to lead compounds by optimizing the protein-ligand binding affinity
Share this article